The prospect and challenge of liquid biopsy in the diagnosis and treatment of chest malignancy.
10.3760/cma.j.cn112150-20221108-01082
- Author:
Li Fang MA
1
;
Bing Jie ZENG
2
;
Xian Zhao WANG
2
;
Xiao ZHANG
3
;
Jia Yi WANG
1
Author Information
1. Department of Clinical Laboratory, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China Institute of Thoracic Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China.
2. Department of Clinical Laboratory, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China.
3. Institute of Thoracic Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China.
- Publication Type:Journal Article
- MeSH:
Humans;
Circulating Tumor DNA/genetics*;
Liquid Biopsy/methods*;
Neoplastic Cells, Circulating/pathology*;
China;
Biomarkers, Tumor
- From:
Chinese Journal of Preventive Medicine
2023;57(7):968-975
- CountryChina
- Language:Chinese
-
Abstract:
In recent years, the incidence of chest malignant tumors in China has increased year by year, which has seriously threatened the health problems of people. Among them, early screening and intervention of patients with chest malignancies is the key to cancer prevention. Early detection, early diagnosis, and early treatment as the "three early prevention" of clinical practice are conducive to improve the survival rate of tumor patients. As a non-invasive and real-time reflection of tumor status, liquid biopsy has gradually received attention in clinical diagnosis and treatment. Circulating tumor cells (CTCs), circulating tumor DNA (ctDNA) and exosomes as liquid biopsy "Three carriages" are not only widely used in the diagnosis, monitoring and prognostic evaluation of chest malignancies, but also face many unknown challenges. In this article, the application of liquid biopsy in chest malignancies in recent years is elaborated in detail, which provides a reference for the formulation of clinical tumor prevention and diagnosis and treatment strategies.
